Open

Ravulizumab/placebo for Lupus Nephritis or IgA Nephropathy

Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Age & Gender

18 years ~ 75 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

The study will have blood pressure measurements, physical exams, blood draws, urine collection including 24 hour urine collection, quality of life surveys and study drug/placebo intravenous infusion. You will also need to be vaccinated against some specific diseases.

Incentives

information provided upon request, mileage reimbursement

In-person visits:
18

Phone or online visits:
2

Total length of participation:
1 year and 8 months

Looking for Specific Volunteers

Able to participate:

Lupus nephritis or IgA Nephropathy
protein present in the urine
not transplanted or planning to be transplanted
not on dialysis or soon to start dialysis

Not eligible if:

you are pregnant or breastfeeding or planning to be pregnant

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Amy Mottl
Medicine-Nephrology

Study Type

Clinical or Medical
Interventional

Study Topics

Kidneys and Liver

IRB Number

20-3399

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.